摘要
目的探讨沙美特罗替卡松粉吸入剂联合布地奈德治疗支气管哮喘急性发作的临床效果。方法选择2017年5月至2018年5月本院收治的138例支气管哮喘急性发作患者作为研究对象,随机将其分为对照组和观察组,各69例。对照组给予布地奈德雾化吸入治疗,观察组在对照组基础上加用沙美特罗替卡松粉吸入剂治疗。比较两组临床疗效、主要症状消失时间、治疗前、后日间和夜间症状评分、肺功能指标、血气指标及不良反应发生情况。结果观察组的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。观察组咳嗽、肺部啰音、呼吸困难及喘息消失时间显著短于对照组(P<0.05)。治疗后,两组日间和夜间症状评分均显著降低,且观察组显著低于对照组(P<0.05)。治疗后,两组患者FEV1、FVC、FEV1/FVC及PEF水平均显著升高,且观察组显著高于对照组(P<0.05)。治疗后,两组患者PaO2、PaCO2、SaO2水平均显著改善,且观察组显著优于对照组(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论沙美特罗替卡松粉吸入剂联合布地奈德治疗支气管哮喘急性发作效果显著,能显著缩短症状消失时间,缓解日间和夜间症状,改善患者肺功能和血气指标,安全性较高,值得推广与应用。
Objective To investigate the clinical effect of salmeterol xinafoate and fluticasone propionate powder for inhalation combined with budesonide in the treatment of acute attack of bronchial asthma.Methods A total of 138 patients with acute attack of bronchial asthma treated in our hospital from May 2017 to May 2018 were randomly divided into control group and observation group, with 69 cases in each group.The control group was treated with budesonide atomization inhalation, the observation group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation on the basis of the control group.The clinical efficacy, disappearance time of major symptoms, scores of daytime and nocturnal symptoms, pulmonary function indexes, blood gas indexes before and after treatment and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).The disappearance time of cough, lung rale, dyspnea and wheezing in the observation group were significantly shorter than those in the control group (P<0.05).After treatment, the scores of daytime and nocturnal symptoms in the two groups decreased significantly, and those of the observation group were significantly lower than the control group (P<0.05).After treatment, the levels of FEV1, FVC, FEV1/FVC and PEF in the two groups increased significantly, and those of the observation group were significantly higher than the control group (P<0.05).After treatment, the levels of PaO2, PaCO2 and SaO2 in the two groups improved significantly, and those of the observation group were significantly better than the control group (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation combined with budesonide in the treatment of acute attack of bronchial asthma has a good effect.It can significantly shorten the disappearance time of major symptoms, relieve daytime and nocturnal symptoms, and improve pulmonary function and blood gas indexes, with higher safety, which is worthy of popularition and application.
作者
屈建辉
QU Jian-hui(the Sixth People's Hospital of Baoji,Baoji 721006,China)
出处
《临床医学研究与实践》
2019年第15期28-30,共3页
Clinical Research and Practice
关键词
沙美特罗替卡松粉吸入剂
布地奈德
支气管哮喘
急性发作
salmeterol xinafoate and fluticasone propionate powder for inhalation
budesonide
bronchial asthma
acute attack
